Fosmidomycin

Drug Profile

Fosmidomycin

Alternative Names: FR 31564

Latest Information Update: 16 May 2007

Price : $50

At a glance

  • Originator Jomaa Pharmaka; Justus Liebig University
  • Developer Jomaa Pharmaka
  • Class Antibacterials; Organophosphorus compounds; Phosphonic acids; Small molecules
  • Mechanism of Action Oxidoreductase inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malaria; Urinary tract infections

Most Recent Events

  • 06 Dec 2001 No-Development-Reported for Malaria in Germany (Unknown route)
  • 27 Apr 2000 A preclinical study has been added to the Parasitic Infections pharmacodynamics section
  • 22 Sep 1999 Preclinical development for Malaria in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top